KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Twist Bioscience (TWST) over the last 9 years, with Sep 2025 value amounting to $183.0 million.

  • Twist Bioscience's Cash & Equivalents fell 19.12% to $183.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.0 million, marking a year-over-year decrease of 19.12%. This contributed to the annual value of $183.0 million for FY2025, which is 19.12% down from last year.
  • Per Twist Bioscience's latest filing, its Cash & Equivalents stood at $183.0 million for FY2025, which was down 19.12% from $226.3 million recorded in FY2024.
  • Twist Bioscience's 5-year Cash & Equivalents high stood at $465.8 million for FY2021, and its period low was $183.0 million during FY2025.
  • Over the past 3 years, Twist Bioscience's median Cash & Equivalents value was $226.3 million (recorded in 2024), while the average stood at $231.9 million.
  • As far as peak fluctuations go, Twist Bioscience's Cash & Equivalents soared by 397.32% in 2021, and later declined by 24.35% in 2023.
  • Twist Bioscience's Cash & Equivalents (Yearly) stood at $465.8 million in 2021, then dropped by 18.71% to $378.7 million in 2022, then dropped by 24.35% to $286.5 million in 2023, then declined by 21.00% to $226.3 million in 2024, then fell by 19.12% to $183.0 million in 2025.